HIGHLIGHTS
- who: Irene Appolloni and collaborators from the Department of Experimental Medicine (DIMES), University of Genova, Genova, Italy have published the Article: Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma, in the Journal: Viruses 2021, 13, 1677. of 14/07/2021
- what: In all the experiments the NOD.CB17-Prkdcscid/NCrHsd strain (Envigo), hereinafter referred to as NOD/SCID, was used. This work was purposely designed to fill this gap, and the authors chose to test an oHSV targeting EGFRvIII endogenously expressed by a relevant fraction of human glioblastomas. The results obtained . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.